Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Background/Aims Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences affect long-term cardiovascular risk. Here, we aime...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Korean Association for the Study of the Liver
2024-01-01
|
| Serier: | Clinical and Molecular Hepatology |
| Fag: | |
| Online adgang: | http://e-cmh.org/upload/pdf/cmh-2023-0328.pdf |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|